Sakar Healthcare (SAKAR) — Financial Results

📢 Key Event
Sakar Healthcare disclosed un-audited Q1FY27 financial results and operational highlights for the quarter ended June 30, 2026.

🔄 What Changed
Revenue grew 38% YoY to ₹7,297 lakhs; EBITDA up 67% YoY to ₹2,125 lakhs; PAT surged 120% YoY to ₹1,028 lakhs.

🔮 What's Next
The company stated it is transitioning to an integrated, regulatory-driven business model to improve supply-chain control, margin visibility, and scalability, positioning for sustained earnings momentum through its oncology pipeline.

💡 Investor Takeaway
The company is shifting toward high-margin oncology exports with strong regulatory progress, driving profitability and growth momentum.

Sakar Healthcare Limited reported Q1FY27 consolidated revenue of ₹7,297 lakhs, up 38% YoY, driven by oncology product expansion and new market authorizations. EBITDA rose 67% YoY to ₹2,125 lakhs with 29% margins, while PAT reached ₹1,028 lakhs, a 120% YoY increase, reflecting strong operating leverage and cost discipline. The company highlighted 65 oncology product contracts executed and 16 EU Marketing Authorisations granted, underscoring its transition to an integrated oncology-focused CDMO model. Forward-looking statements indicate continued growth through pipeline development and regulatory approvals, though risks include market volatility and execution risks in international markets.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SAKAR ✨ Ask AI About This

About Sakar Healthcare Limited (SAKAR)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,550.15 Cr P/E: 102.3

View full SAKAR stock details →

📡 Get AI alerts when SAKAR files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SAKAR — Free

💡 Ask AI about this filing

"What is Sakar Healthcare's oncology pipeline valuation and revenue contribution?" "How does Sakar's EU Marketing Authorisations compare to peers in oncology?" "What is the projected capex for the Bavla oncology facility expansion?"

Ask AI Free →

📊 More SAKAR filings

See all SAKAR filings →

🔥 Also filed on 28 July 2026

LT Larsen & Toubro Limited Corporate Action TI Tilaknagar Industries Limited Financial Results LGBBROSLTD LG Balakrishnan & Bros Limited Announcement MAXIND Max India Limited Annual Report RVNL Rail Vikas Nigam Limited Corporate Action NIRAJ Niraj Cement Structurals Limited Offer Document

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SAKAR files new disclosures

Track SAKAR filings, board meetings, and corporate actions. Free email alerts at 5 PM.